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Abstract: 
Background: The Choosing Wisely UK campaign aims to promote shared decision making between 
patients and clinicians, helping people choose care that is supported by evidence, free from harm, truly 
necessary and consistent with their values. The Academy of Medical Royal Colleges (AoMRC), which 
coordinates the campaign, invited the BSR to submit 3-6 recommendations in 2018. The audience 
includes patients; rheumatologists and other physicians; GPs; nurses; allied health professionals. 
Methods: The 14-member working group included two patient contributors, one consultant nurse, six 
consultant rheumatologists, one GP staff grade rheumatologist, two rheumatology trainees and two 
immunologists. The National Rheumatoid Arthritis Society and Versus Arthritis were represented. The 
working group was convened and recommendation development completed within 12 weeks. For the first 
part of the abbreviated Delphi-exercise, working group members submitted proposed recommendations 
with an accompanying evidence summary. These were collated and distributed (verbatim and 
anonymously) to the group to inform a ranking exercise. Members rated each topic from 5 (highest) to 1 
(lowest) anonymously and left remaining topics unscored; topics with the highest scores were selected. A 
subgroup, including patient contributors, met to draft the recommendations. Evidence summaries were 
collated from information submitted in the initial proposals and from further contributions from working 
group members. External experts were consulted on each recommendation, following which consensus 
was sought from the working group to ratify the recommendations. 
Results: Thirty-two proposals were received on 14 discrete clinical topics, from 10 working group 
members. Twelve members ranked topics. Six final recommendations were developed, all of which were 
endorsed by the BSR. The AoMRC accepted all six recommendations, proposing that ANA+ENA and 
C3/C4/dsDNA had clinician facing-recommendations only, due to their technical nature (table 1).Table 1. 
BSR Choosing Wisely UK Recommendations 
Topic Our Patient Recommendations Our Clinician Recommendations 
ANA & ENAs - 
Testing ANA and ENAs should be 
reserved for patients suspected to have a 
diagnosis of a connective tissue disease, 
e.g. lupus. Testing ANA and ENAs should 
be avoided in the investigation of 
widespread pain or fatigue alone. Repeat 
testing is not normally indicated unless the 
clinical picture changes significantly. 
Rheumatoid 
Arthritis 
If a doctor suspects that you have 
rheumatoid arthritis, it is recommended 
that you are referred to rheumatology 
without delay, even before any tests are 
done. There is no single blood test which 
can determine whether someone does or 
does not have rheumatoid arthritis. 
Patients with suspected inflammatory 
arthritis should be referred to 
Rheumatology without delay. Rheumatoid 
factor and CCP/ACPA are important, but 
should be avoided as screening tests. A 
negative result does not exclude 
rheumatoid arthritis, nor does a positive 
result equate to a diagnosis of rheumatoid 
arthritis. Repeat testing is not normally 
indicated. 
Vitamin D 
It is important for everyone to take 
Vitamin D supplements during winter. If 
you have restricted access to sunlight (e.g. 
if you live in a care home or cover your 
skin), or have dark skin, it is recommended 
that you take a supplement all year round. 
Vitamin D testing is unlikely to be useful 
or necessary in most people and future 
testing is not normally needed for those 
taking supplements. 
Everyone should consider Vitamin D 
supplementation during winter. People 
who have restricted access to sunlight (e.g. 
those living in institutions or who cover 
their skin), or have dark skin, should 
consider supplementation all year round. 
Vitamin D testing should be reserved for 
people at high risk from deficiency and 
avoided as part of routine investigation of 
widespread pain alone. Repeat testing is 
not normally indicated in those taking 
supplements. 
Osteoporosis 
Bisphosphonates are drugs that help 
reduce fracture risk due to bone thinning 
(osteoporosis). People who take 
bisphosphonate treatment should discuss 
this with their healthcare professional 
every 3-5 years because it may be 
advisable for some to have a break in 
treatment. 
Bisphosphonate therapy should be 
reviewed with every patient after 3-5 
years, and a treatment holiday considered. 
This should follow a shared-decision 
making conversation which includes the 
risks and benefits of continued treatment. 
Steroid 
injections 
It is recommended that you have a 
conversation with your healthcare 
professional before accepting steroid 
injections for non-inflammatory 
musculoskeletal conditions. So that you 
can make an informed decision, this 
discussion should include the risks, 
benefits, and alternatives such as exercise 
and physical therapy. Although some 
people may experience short term benefit, 
there are potential long-term risks with 
repeated injections. 
The use of intra-articular and soft-tissue 
steroid injections for non-inflammatory 
musculoskeletal conditions should be 
preceded by consideration of non-invasive 
alternatives such as exercise and physical 
therapy. Consent to any invasive procedure 
such as this must arise from a shared-
decision making conversation with every 
patient, which includes assessment of the 
risks and benefits. 
C3, C4 & 
dsDNA in 
- 
C3, C4 and dsDNA are important tests to 
help in the diagnosis and assessment of 
disease activity in lupus. They should be 
connective 
tissue disease 
reserved for specialist monitoring of 
disease activity and should be avoided as 
screening tests. 
 
Conclusion: Six recommendations were developed by a multidisciplinary team including people with 
arthritis. Because of the robust development process, we believe these recommendations are acceptable, 
meaningful and practical. Their application will lead to more personalised care, increased patient and 
clinician satisfaction, and better use of limited resources. We encourage all BSR members to engage with 
and champion these recommendations to inform shared decision-making conversations with patients. 
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